Esperion Therapeutics Inc (NAS:ESPR)
$ 2.18 0.02 (0.93%) Market Cap: 413.02 Mil Enterprise Value: 448.77 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Esperion Therapeutics Inc Analyst and Investor Day Transcript

Jun 13, 2019 / 01:00PM GMT
Release Date Price: $50.09 (+1.03%)
Alexander Duke Schwartz
Esperion Therapeutics, Inc. - Senior Director of IR

Hello. All right. Perfect. Thank you, everyone. If you can just take your seats, we're about to get started right now. So hi, everyone. I'm Alex Schwartz. I head Investor Relations here at Esperion, and welcome to our 2019 Investor and Analyst Day. I'm excited for what we have planned for you today.

First, you're going to be hearing some new stuff from us. You're going to meet our highly experienced and successful commercial leadership team. You're going to be learning about launch plans for bempedoic acid and the bempedoic acid combination tablet in the United States. And finally, you're going to get the chance to ask a lot of questions.

Before we get into today's events, I just want to take a moment to point out this slide. The presentation we're making and the accompanying statements are forward-looking in nature. They are covered under the Safe Harbor Provisions Act.

Now I'd like to draw your attention to today's agenda. Throughout today, you'll be hearing from members of our Lipid Management Team

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot